Similar to our FISH and IHC analysis, Tsutsui and colleagues [19] found the combination of HER1 and HER2 expression in breast cancer to have a severe negative impact on disease outcome compared with normal protein levels, whereas the prognostic value of HER2 overexpression seemed more pronounced than HER1 overexpression. This evidence concerns the gene ERBB2 and breast carcinoma.